

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 49/00	A2	(11) International Publication Number: WO 00/24429 (43) International Publication Date: 4 May 2000 (04.05.00)
(21) International Application Number: PCT/GB99/03488 (22) International Filing Date: 22 October 1999 (22.10.99) (30) Priority Data: 9823175.6 22 October 1998 (22.10.98) GB (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/107212 (CIP) Filed on 5 November 1998 (05.11.98) (71) Applicant (for all designated States except US): NYCOMED IMAGING AS [NO/NO]; Nycoveien 1-2, N-0401 Oslo (NO). (71) Applicant (for GB only): GOLDING, Louise [GB/GB]; 179 Queen Victoria Street, London EC4V 4EL (GB). (72) Inventor; and (75) Inventor/Applicant (for US only): KELLAR, Kenneth [US/US]; Nycomed Inc., 466 Devon Park Drive, P.O. Box 6630, Wayne, PA 19087-8630 (US).		(74) Agents: GOLDING, Louise et al.; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB). (81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), DM, EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: COMPOUND (57) Abstract <p>The invention relates to the use as a contrast agent in MR imaging of a physiologically tolerable lanthanide compound or salt thereof having first and second oxidation states which differ in relaxivity by a factor of at least 5, and which is convertible <i>in vivo</i> from said first to said second oxidation state whereby contrast is enhanced in a body region in which conversion to said second state does or does not occur.</p>		